microRNA-150 targets major epigenetic repressors and inhibits cell proliferation

Selvam, Murugan; Bandi, Venkateshwarlu; Ponne, Saravanaraman; Ashok, Cheemala; Baluchamy, Sudhakar

doi:10.1016/j.yexcr.2022.113110

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… miRNA name Chromosomal location Functions References 1 miR-185 Chr22 Represses cells growth and metastasis of osteosarcoma cells by targeting cathepsin E ( Wu et al., 2022 ) 2 miR-338-3p Chr17 Enhances the proliferation of osteosarcoma cells by regulating the HIF-1/Rap1/PI3K-Akt pathway ( Li et al., 2021 ) 3 miR-365 Chr16 Helps in the progression of OP by inhibiting osteogenic differentiation by targeting RUNX2 Cheng et al. (2019) 4 miR-150 Chr19 Act as major epigenetic repressors and inhibits cell proliferation Selvam et al. (2022) 5 miR-214 Chr1 Inhibits the osteoblast function by targeting ATF4 protein and promotes the function of osteoclast through phosphatase and tensin homolog Wang et al.…”

Section: Therapeutic Role Of Mirna In Several Bone Diseasesmentioning

confidence: 99%

Recent advancements of miRNAs in the treatment of bone diseases and their delivery potential

Sharma

Lee

2023

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

Section: Therapeutic Role Of Mirna In Several Bone Diseasesmentioning

confidence: 99%

Recent advancements of miRNAs in the treatment of bone diseases and their delivery potential

Sharma

Lee

2023

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

Impact of JQ1 treatment on seizures, hippocampal gene expression, and gliosis in a mouse model of temporal lobe epilepsy

Harnett,

Mathoux,

Wilson

et al. 2024

Eur J of Neuroscience

View full text Add to dashboard Cite

Epilepsy is a neurological disease characterised by recurrent seizures with complex aetiology. Temporal lobe epilepsy, the most common form in adults, can be acquired following brain insults including trauma, stroke, infection or sustained status epilepticus. The mechanisms that give rise to the formation and maintenance of hyperexcitable networks following acquired insults remain unknown, yet an extensive body of literature points towards persistent gene and epigenomic dysregulation as a potential mediator of this dysfunction. While much is known about the function of specific classes of epigenetic regulators (writers and erasers) in epilepsy, much less is known about the enzymes, which read the epigenome and modulate gene expression accordingly. Here, we explore the potential role for the epigenetic reader bromodomain and extra‐terminal domain (BET) proteins in epilepsy. Using the intra‐amygdala kainic acid model of temporal lobe epilepsy, we initially identified widespread dysregulation of important epigenetic regulators including EZH2 and REST as well as altered BRD4 expression in chronically epileptic mice. BRD4 activity was also notably affected by epilepsy‐provoking insults as seen by elevated binding to and transcriptional regulation of the immediate early gene Fos. Despite influencing early aspects of epileptogenesis, blocking BET protein activity with JQ1 had no overt effects on epilepsy development in mice but did alter glial reactivity and influence gene expression patterns, promoting various neurotransmitter signalling mechanisms and inflammatory pathways in the hippocampus. Together, these results confirm that epigenetic reader activity is affected by epilepsy‐provoking brain insults and that BET activity may exert cell‐specific actions on inflammation in epilepsy.

show abstract

MicroRNA: A Signature for the Clinical Progression of Chronic Lymphocytic Leukemia

Veryaskina,

Titov,

Kovynev

et al. 2024

Lymphatics

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most common human leukemia. The disease is caused by abnormal proliferation and development of lymphocytes and their precursors in the blood and bone marrow (BM). Recent studies have shown that the CLL’s clinical course and outcome depend not only on genetic but also epigenetic factors. MicroRNAs (miRNAs) are involved in the development of hematological tumors, including CLL. The aim of this study is to identify the miRNA expression profile in CLL and determine the role of miRNAs in biological pathways associated with leukemogenesis in CLL. The following samples were used in this study: (1) samples obtained by sternal puncture and aspiration biopsy of BM (n = 115). They included samples from 21 CLL patients with anemia and indications for therapy and 45 CLL patients without anemia and with indications for therapy. The control group for the CLL BM samples consisted of patients with non-cancerous blood diseases (n = 35). (2) Lymph node (LN) samples (n = 20) were collected from CLL patients. The control group for the CLL LN samples consisted of patients with lymphadenopathy (n = 37). All cases were patients before treatment. We demonstrated a significant upregulation of miRNA-34a and miRNA-150 in CLL BM samples (p < 0.05) and downregulation of miRNA-451a in CLL LN samples (p < 0.05). We noted a dynamic increase in the levels of miRNA-150 and miRNA-34a in BM at various stages of tumor progression of CLL. We concluded that a dynamic picture of clinical manifestations of CLL closely correlates with changes in epigenetic characteristics of the tumor. Progression of the lymphoproliferative process and indications for cytoreductive therapy are associated with changes in the miRNA profile generated by cancer cells in different sites of clonal expansion.

show abstract

microRNA-150 targets major epigenetic repressors and inhibits cell proliferation

Cited by 3 publications

References 41 publications

Recent advancements of miRNAs in the treatment of bone diseases and their delivery potential

Recent advancements of miRNAs in the treatment of bone diseases and their delivery potential

Impact of JQ1 treatment on seizures, hippocampal gene expression, and gliosis in a mouse model of temporal lobe epilepsy

MicroRNA: A Signature for the Clinical Progression of Chronic Lymphocytic Leukemia

Contact Info

Product

Resources

About